Skip to main content
. 2021 Dec 24;8(2):e001849. doi: 10.1136/openhrt-2021-001849

Figure 2.

Figure 2

Proportion of patients requiring hospitalisation for (A) hypertension and (B) heart failure events among all reported events stratified based on the use of the type of combination with either taxanes or vinca alkaloids from 2010 to 2020. Refer to tables 1 and 2 to see the total number of reported events to know the denominator for these events.